Alex C. Levit - 19 Feb 2026 Form 4 Insider Report for Context Therapeutics Inc. (CNTX)

Reporting relationship: Chief Legal Officer, Corp. Sec
Issuer ticker: CNTX
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2026, 16:24:53 UTC
Prior SEC filing: 10 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Alex Levit, Attorney-in-Fact

Key filing fact

Alex C. Levit filed Form 4 for Context Therapeutics Inc. (CNTX) on 23 Feb 2026.

Key facts

This page summarizes Alex C. Levit's Form 4 filing for Context Therapeutics Inc. (CNTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 16:24.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001862840 Primary reporting owner

Levit Alex C.

Relationship: Chief Legal Officer, Corp. Sec
Address: 2001 MARKET STREET, SUITE 3915, UNIT #15, PHILADELPHIA
Signature: /s/ Alex Levit, Attorney-in-Fact
Signature date: 23 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +270,000
Change %
Price: $0.000000
Shares after: 270,000
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 270,000
Exercise price: $2.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.